THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING has a total of 26 patent applications. It increased the IP activity by 100.0%. Its first patent ever was published in 2013. It filed its patents most often in Canada, United States and Australia. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and environmental technology are THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING, HANGZHOU INNOGATE PHARMA CO LTD and MNEMOSYNE PHARMACEUTICALS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Canada | 8 | |
#2 | United States | 6 | |
#3 | Australia | 4 | |
#4 | Israel | 3 | |
#5 | China | 2 | |
#6 | Republic of Korea | 1 | |
#7 | Peru | 1 | |
#8 | Philippines | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Environmental technology | |
#4 | Measurement |
# | Name | Total Patents |
---|---|---|
#1 | Helleday Thomas | 22 |
#2 | Scobie Martin | 21 |
#3 | Koolmeister Tobias | 19 |
#4 | Jacques Sylvain | 18 |
#5 | Desroses Matthieu | 10 |
#6 | Homan Evert | 9 |
#7 | Jacques-Cordonnier Marie-Caroline | 9 |
#8 | Wallner Olov | 9 |
#9 | Henriksson Carl Martin | 7 |
#10 | Vallin Karl Sven Axel | 7 |
Publication | Filing date | Title |
---|---|---|
AU2015329955A1 | Heterocyclic compounds as DCTPP1 modulators | |
AU2015268962A1 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | |
US2016002175A1 | Pyrimidine-2,4-diamine derivatives for treatment of cancer |